Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current knowledge of neuropathy and monoclonal gammopathy of undetermined significance (MGUS). Roughly 20% of patients with MGUS experience some level of neuropathy, though the relationship between MGUS and nerve damage is poorly understood. This, combined with a limited number of studies on MGUS, poses a challenge when choosing the most appropriate therapies for patients. Dr Castillo highlights current treatment approaches, which focus on reducing plasma IgM levels, and discusses other unmet needs in this space. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.